Sodium Bicarbonate (Baking Soda)

By increasing blood bicarbonate, it enhances the efflux of H+ and lactate from working muscle, delaying the pH drop that impairs contraction. Meta-analyses consistently show ~1.5–2% improvements in efforts lasting 30 seconds to 10 minutes (rowing, swimming, 800m running, cycling time trials). This is strong, repeatedly replicated evidence.

Supplementation can increase repetitions to failure and total work completed across repeated sets or sprint intervals, particularly when rest periods are short. Over weeks this may translate into larger training adaptations. Evidence is moderate — acute effects are well documented, chronic adaptation data are fewer.

Bicarbonate is the body's main extracellular buffer; oral loading raises the reservoir available to soak up metabolic protons. Blood pH and bicarbonate reliably rise 60–180 minutes post-dose, and blood lactate is typically higher post-exercise (reflecting better efflux from muscle). This mechanism is very well characterised physiologically.

Raising urine pH reduces the formation of uric acid and cystine stones and can aid clearance of certain drug overdoses. Alkali therapy (often as citrate, but bicarbonate works similarly) is used clinically for this purpose. Evidence is strong in clinical settings, though potassium citrate is usually preferred to avoid a sodium load.

In CKD patients with low serum bicarbonate, oral sodium bicarbonate corrects acidosis, may preserve residual kidney function, reduce muscle wasting, and improve nutritional status. Several randomised trials support this, though results are mixed and it must be prescribed and monitored by a physician.

For performance, take 60–180 minutes before the event — peak blood bicarbonate typically occurs 60–90 minutes after a single dose, but individual time-to-peak varies widely, so test your personal timing in training. Splitting the dose over 30–60 minutes, or using a serial-loading protocol (0.4–0.5 g/kg/day split into 3–4 doses for 3–5 days), reduces GI distress. For clinical alkalinisation, doses

Take with a small carbohydrate-rich, low-fat, low-fibre meal and 500–1000 ml of water — this substantially reduces nausea, bloating and diarrhoea compared with taking it on an empty stomach. Avoid taking it with large fatty or high-fibre meals, and do not take it within 1–2 hours of medications whose absorption is pH-sensitive.

Ergogenic dose is 0.2–0.3 g per kg body weight (typically 15–20 g for a 70 kg person); 0.3 g/kg is the most studied, with little added benefit and much more GI upset above this. As an antacid, roughly half a teaspoon (about 2 g) in water. Clinical CKD dosing is individualised by a physician based on serum bicarbonate.

Plain sodium bicarbonate powder dissolved in a large volume of water or flavoured drink is cheapest and effective. Enteric-coated or hydrogel/delayed-release capsules (e.g. Bicarb Balance-type products) markedly reduce gastrointestinal side effects and are worth the cost if you react badly to the powder. Sodium citrate is an alternative if bicarbonate is intolerable.

A 20 g dose delivers roughly 5.5 g of sodium — a major consideration for anyone with hypertension, heart failure, or kidney disease. Never use for chronic self-treatment of reflux. Separate from other medications by at least 2 hours because raising gastric pH alters drug absorption.

Oral bicarbonate is a standard treatment when serum bicarbonate falls below roughly 22 mmol/L, correcting acidosis and potentially slowing GFR decline and protein catabolism. Randomised trials support benefit, though sodium load and blood pressure must be monitored. Prescription-level use only.

Alkalinising urine to pH 6.5–7 markedly increases uric acid solubility and reduces stone recurrence. Bicarbonate achieves this, though potassium citrate is generally first-line because it avoids sodium loading and adds citrate's own stone-inhibiting effect. Evidence is strong.

Both proximal (type 2) and distal (type 1) RTA are managed with alkali therapy to correct chronic acidosis, prevent growth failure in children, and reduce nephrocalcinosis and bone disease. Bicarbonate or citrate is the mainstay of treatment with well-established clinical evidence.

A small human study found oral bicarbonate shifted splenic and blood immune cells toward an anti-inflammatory phenotype, possibly via a cholinergic signal from stomach mesothelial cells. This is preliminary mechanistic work in healthy volunteers and rodents — not a validated treatment.

A half-teaspoon in water neutralises gastric acid quickly for short-term relief. Not appropriate for chronic reflux due to sodium content, acid rebound, and risk of milk-alkali syndrome with repeated high doses. Evidence supports acute symptom relief only.

Beta-alanine raises intramuscular carnosine, an intracellular buffer, while bicarbonate buffers the extracellular compartment — the two act at different sites. Several studies show additive or complementary performance benefits when combined, making this one of the best-supported stacks for high-intensity exercise. View Beta-alanine guide →

Creatine supports phosphocreatine resynthesis and power output in the first 10–30 seconds, while bicarbonate helps in the 30-second to 10-minute window. Combining them covers a broader intensity spectrum; some trials show additive effects on repeated sprint work, though results are mixed. View Creatine monohydrate guide →

Caffeine reduces perceived exertion and enhances central drive via adenosine antagonism — a mechanism entirely separate from pH buffering. Co-ingestion has produced additive gains in some time-trial and repeated-sprint studies, though caffeine may worsen GI discomfort in sensitive individuals. View Caffeine guide →

An alternative extracellular alkalising agent that also raises blood bicarbonate but is generally better tolerated gastrointestinally. It can be used instead of, or partly in place of, bicarbonate to reach a target alkalosis with fewer stomach symptoms; evidence for ergogenic effect is moderate. View Sodium citrate guide →

For urinary alkalinisation and stone prevention, potassium citrate delivers alkali without a sodium load and adds citrate, which directly inhibits calcium stone formation. Often the preferred clinical partner or substitute where blood pressure or sodium intake is a concern. View Potassium citrate guide →

Sodium bicarbonate is itself a classic antacid, neutralising gastric hydrochloric acid by an identical acid–base reaction, just faster and more short-lived. The mechanistic overlap is complete and the evidence for acute symptom relief is long-established, though bicarbonate causes more gas and sodium loading.

Both are systemic alkalinising agents that raise serum bicarbonate and urine pH, used for renal tubular acidosis, metabolic acidosis and uric acid stone prevention. Citrate is metabolised to bicarbonate in the liver, so the end effect is essentially the same; evidence for equivalence in alkalinisation is strong, though citrate adds independent anti-stone activity.

An intravenous buffer used in hospitals for severe metabolic acidosis, sharing bicarbonate's core function of consuming excess hydrogen ions to raise pH. Bicarbonate is the more commonly used agent; the mechanistic parallel is direct, though THAM works without generating CO2.

Acetazolamide inhibits carbonic anhydrase, causing bicarbonate loss and metabolic acidosis — essentially the pharmacological opposite of bicarbonate loading, and the two can be used to offset each other clinically. Notable because they act on the same bicarbonate–CO2 buffer system in opposite directions, a well-documented interaction.